Tolerability and efficacy of classical CMF (cCMF) using oral cyclophosphamide (OC) vs intravenous cyclophosphamise (IVC) in early stage breast cancer: A non-randomised comparison of patients (pts) treated in the National Epirubicin Adjuvant Trial (NEAT)  40th Annual American Society of Slinical Oncology meeting. New Orleans, Louisiana USA June 2004

DW Hiller; L Earl; HM Dunn; Sarah Bathers; David Spooner; R Grieve; RK Agrawal

Tolerability and efficacy of classical CMF (cCMF) using oral cyclophosphamide (OC) vs intravenous cyclophosphamise (IVC) in early stage breast cancer: A non-randomised comparison of patients (pts) treated in the National Epirubicin Adjuvant Trial (NEAT) 40th Annual American Society of Slinical Oncology meeting. New Orleans, Louisiana USA June 2004

DW Hiller
, L Earl
, HM Dunn
, Sarah Bathers
, David Spooner
, R Grieve
, RK Agrawal

Cancer and Genomic Sciences

Research output: Contribution to journal › Article

Original language	English
Pages (from-to)	595S
Journal	Journal of Clinical Oncology
Volume	22 (14)
Publication status	Published - 1 Jan 2007

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Hiller, DW., Earl, L., Dunn, HM., Bathers, S., Spooner, D., Grieve, R., & Agrawal, RK. (2007). Tolerability and efficacy of classical CMF (cCMF) using oral cyclophosphamide (OC) vs intravenous cyclophosphamise (IVC) in early stage breast cancer: A non-randomised comparison of patients (pts) treated in the National Epirubicin Adjuvant Trial (NEAT) 40th Annual American Society of Slinical Oncology meeting. New Orleans, Louisiana USA June 2004. Journal of Clinical Oncology , 22 (14), 595S.

Hiller, DW ; Earl, L ; Dunn, HM et al. / Tolerability and efficacy of classical CMF (cCMF) using oral cyclophosphamide (OC) vs intravenous cyclophosphamise (IVC) in early stage breast cancer: A non-randomised comparison of patients (pts) treated in the National Epirubicin Adjuvant Trial (NEAT) 40th Annual American Society of Slinical Oncology meeting. New Orleans, Louisiana USA June 2004. In: Journal of Clinical Oncology . 2007 ; Vol. 22 (14). pp. 595S.

@article{05a85b84fb194a0f80dda78d27703126,

title = "Tolerability and efficacy of classical CMF (cCMF) using oral cyclophosphamide (OC) vs intravenous cyclophosphamise (IVC) in early stage breast cancer: A non-randomised comparison of patients (pts) treated in the National Epirubicin Adjuvant Trial (NEAT) 40th Annual American Society of Slinical Oncology meeting. New Orleans, Louisiana USA June 2004",

author = "DW Hiller and L Earl and HM Dunn and Sarah Bathers and David Spooner and R Grieve and RK Agrawal",

year = "2007",

month = jan,

day = "1",

language = "English",

volume = "22 (14)",

pages = "595S",

journal = "Journal of Clinical Oncology ",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

}

Hiller, DW, Earl, L, Dunn, HM, Bathers, S, Spooner, D, Grieve, R & Agrawal, RK 2007, 'Tolerability and efficacy of classical CMF (cCMF) using oral cyclophosphamide (OC) vs intravenous cyclophosphamise (IVC) in early stage breast cancer: A non-randomised comparison of patients (pts) treated in the National Epirubicin Adjuvant Trial (NEAT) 40th Annual American Society of Slinical Oncology meeting. New Orleans, Louisiana USA June 2004', Journal of Clinical Oncology , vol. 22 (14), pp. 595S.

Tolerability and efficacy of classical CMF (cCMF) using oral cyclophosphamide (OC) vs intravenous cyclophosphamise (IVC) in early stage breast cancer: A non-randomised comparison of patients (pts) treated in the National Epirubicin Adjuvant Trial (NEAT) 40th Annual American Society of Slinical Oncology meeting. New Orleans, Louisiana USA June 2004. / Hiller, DW; Earl, L; Dunn, HM et al.
In: Journal of Clinical Oncology , Vol. 22 (14), 01.01.2007, p. 595S.

Research output: Contribution to journal › Article

TY - JOUR

T1 - Tolerability and efficacy of classical CMF (cCMF) using oral cyclophosphamide (OC) vs intravenous cyclophosphamise (IVC) in early stage breast cancer: A non-randomised comparison of patients (pts) treated in the National Epirubicin Adjuvant Trial (NEAT) 40th Annual American Society of Slinical Oncology meeting. New Orleans, Louisiana USA June 2004

AU - Hiller, DW

AU - Earl, L

AU - Dunn, HM

AU - Bathers, Sarah

AU - Spooner, David

AU - Grieve, R

AU - Agrawal, RK

PY - 2007/1/1

Y1 - 2007/1/1

M3 - Article

SN - 0732-183X

VL - 22 (14)

SP - 595S

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

Hiller DW, Earl L, Dunn HM, Bathers S, Spooner D, Grieve R et al. Tolerability and efficacy of classical CMF (cCMF) using oral cyclophosphamide (OC) vs intravenous cyclophosphamise (IVC) in early stage breast cancer: A non-randomised comparison of patients (pts) treated in the National Epirubicin Adjuvant Trial (NEAT) 40th Annual American Society of Slinical Oncology meeting. New Orleans, Louisiana USA June 2004. Journal of Clinical Oncology . 2007 Jan 1;22 (14):595S.